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The concept of repairing the brain with growth factors has been pursued for many years in a variety 
of neurodegenerative diseases including primarily Parkinson’s disease (PD) using glial cell line-derived 
neurotrophic Factor (GDNF). This neurotrophic factor was discovered in 1993 and shown to have 
selective effects on promoting survival and regeneration of certain populations of neurons including 
the dopaminergic nigrostriatal pathway. These observations led to a series of clinical trials in PD 
patients including using infusions or gene delivery of GDNF or the related growth factor, neurturin 
(NRTN). Initial studies, some of which were open label, suggested that this approach could be of value 
in PD when the agent was injected into the putamen rather than the cerebral ventricles. In subsequent 
double-blind, placebo-controlled trials, the most recent reporting in 2019, treatment with GDNF did 
not achieve its primary end point.  As a result, there has been uncertainty as to whether GDNF (and 
by extrapolation, related GDNF family neurotrophic factors) has merit in the future treatment of PD. 
To critically appraise the existing work and its future, a special workshop was held to discuss and 
debate this issue. This paper is a summary of that meeting with recommendations on whether there 
is a future for this therapeutic approach and also what any future PD trial involving GDNF and other 
GDNF family neurotrophic factors should consider in its design. 
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The discovery and characterisation of specific neurotrophic factors in the context of neuronal 
development and synapse  formation in the last half of the 20th century, led to the hypothesis that 
certain adult neuronal populations lost to chronic disease processes might be rescued and potentially 
regenerated by the administration of these agents [1]. This has been extensively explored in 
Parkinson’s Disease (PD) with the use of GDNF and related factor NRTN and the dopaminergic (DA) 
nigrostriatal pathway- the loss of which is known to be central and critical to the development and 
clinical expression of this condition [2] . 
In this short paper, we critically appraise the pre-clinical and clinical trial work with GDNF and NRTN 
in patients with PD. This appraisal is based on a meeting held over 2 days in August 2019 that brought 
together experts who had direct and practical experience in this field.  The timing of this meeting was 
linked to the recent publication a UK-based clinical trial and parallel airing on the BBC of the two-part 
documentary “The Parkinson’s Drug Trial: A Miracle Cure? 
[https://www.bbc.co.uk/mediacentre/proginfo/2019/09/parkinsons-drug-trial-a-miracle-cure]? The 
meeting was organised and funded by The Cure Parkinson’s Trust and supported by The Michael J Fox 
Foundation and Van Andel Institute. 
THE PRECLINICAL EVIDENCE THAT GDNF CAN RESCUE THE NIGROSTRIATAL PATHWAY  
The discovery of GDNF in 1993 was made at a time of great interest in the therapeutic development 
of neurotrophic factors which offered potential for treating a number of disease states. The search for 
a survival factor with high selectivity for midbrain DA neurons had already been going on for some 
time. As such, when Lin et al reported  the cloning and bioactivity of this new trophic factor in 1993 
there was great excitement [3]. Indeed this in part helps explain why there was such a short time span 
between the first pre-clinical in vivo studies (performed and published in 1994-95) and the first clinical 
trial with this agent [4] which started recruiting patients in July 1996.  
The second member of the GDNF family of ligands, NRTN, was discovered in 1996 [5] along with the 
receptor signaling pathways for these 2 factors [6] . This work revealed that while GDNF and NRTN 
are members of the transforming growth factor beta (TGF-β) family, they signal through a 
completely different receptor system compared to other TGF-β family members. GDNF first binds to 
the Glycosylphosphatidylinositol (GPI)-anchored co-receptor GDNF family receptor alpha-1 (GFRα1) 
and then the GDNF-GFRα1 complex binds to, and activates the transmembrane receptor tyrosine 
kinase RET. NRTN likewise signals to the cells via the RET receptor, but its binding to RET is mediated 
through the GFRα2 co-receptor although when delivered at high levels it also can bind to GFRα1 [6]. 
RET then activates the intracellular mitogen-activated protein kinase (MAPK), Akt (protein kinase B) 
and Src signaling cascades that are responsible for the survival and regeneration of DA neurons. It is 
important to stress that GDNF and NRTN trigger rapid responses in DA neurons through protein 
phosphorylation, but in addition to that they activate a number of transcription factors that have 
longer-lasting effects on DA neurons  
The initial work with GDNF was made possible through having access to a recombinant human form 
of protein from Synergen and Genentech. This enabled the generation of preliminary in vivo data on 
DA neuroprotection in the three rodent PD models available at the time: the rat 6 hydroxydopamine 
(6-OHDA) model [7, 8], the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model [9] 
and the knife-transection model [10]. In addition, a study performed in intact rats showed that GDNF, 
administered into the substantia nigra, could stimulate DA neuronal function [11]. The fact that the 
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findings from all of these studies provided positive evidence in the same direction was re-assuring – 
namely a growth factor that seemed to work on DA neuronal rescue and regeneration.  
These initial preclinical studies used intracerebral administration of GDNF, (single or repeated 
injections of microgram amounts over the substantia nigra). Nevertheless, Amgen, the company that 
had acquired the rights to GDNF, opted for an intraventricular delivery approach in its first clinical trial 
[4] (see below). A critical factor in this decision were the results of a study, sponsored by Amgen, 
reporting significant, dose-dependent beneficial effects obtained by monthly intraventricular 
injections of GDNF in MPTP-treated rhesus monkeys [12]. The results again looked promising: all the 
major motor features (bradykinesia, rigidity, posture and balance) were improved when assessed 4 
weeks after the last (fourth) monthly injection. Doubts on this mode of administration, however, soon 
arose: studies on the distribution of GDNF after intraventricular delivery indicated very limited 
diffusion into the brain parenchyma given its strong binding to extracellular matrix and cell surface 
heparin sulphate proteoglycans [13, 14] . Furthermore a follow-up study by another team, performed 
in the same monkey model, failed to show any protective effect on the MPTP-lesioned DA neurons 
[15].   
While this trial was ongoing, experimental work performed in rodent and primate PD models provided 
further and more compelling evidence that GDNF must be administered directly into the brain 
parenchyma to exert its actions, and that the site, dose and timing of GDNF delivery are important.  
Experiments in 6-OHDA lesioned rats showed that delivery into the substantia nigra could rescue DA 
neuronal cell bodies against toxic damage but failed to protect their axonal projections in the striatum 
[16]. Rescue of both DA neuronal cell bodies and their axons projecting to the striatum required that 
the factor be delivered into the striatum, or into both the striatum and substantia nigra, provided that 
it is given before or soon after the toxin treatment [17]. Furthermore, the timing of the delivery of 
GDNF was also found to be important. In both rodents and primates there was evidence that delayed 
intrastriatal GDNF delivery, starting weeks or months after 6-OHDA or MPTP treatment, could still 
protect surviving DA neurons and stimulate regenerative sprouting from spared axons in the partially 
denervated striatum [18-21]. 
Based on all this experimental data it was concluded that the therapeutic potential of GDNF is due to 
a combination of three interacting mechanisms:  
(i) Protection of midbrain DA neurons against toxin-induced cell death;  
(ii) stimulation of axonal regeneration in the area reached by GDNF; and  
(iii) recovery of function through upregulation of DA turnover and release.  
These experimental studies, performed over the first decade after GDNF´s discovery, were very 
encouraging and stimulated a series of clinical trials, including some where the agent was given intra-
putaminally (see below). At that time, the preclinical data seemed to support such a move to the clinic 
based on all the studies performed in mice, rats and non-human primates. There were, however, 
obvious weaknesses in the pre-clinical data: Firstly GDNF was relatively ineffective in the face of severe 
lesions giving >80% loss of DA neurons which more closely mimics the human condition. Secondly, the 
data showing efficacy was obtained in toxin-based models where 6-OHDA or MPTP are administered 
acutely which results in a degenerative process that is primarily driven by oxidative damage or 
mitochondrial dysfunction not protein aggregation.  Further, these models do not replicate the late 
stages of PD nor the progressive, alpha-synuclein related pathophysiology that is characteristic of the 
human disease. Given this difference, there was a concern that the results obtained in toxin-based 
models may not be predictive for human PD patients receiving this experimental therapy. In addition, 
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there were also concerns about whether the GDNF made at that time using E. coli (as opposed to 
human recombinant protein made in mammalian cells) would work less well in human patients. 
Some of these anxieties have been borne out in more recent experiments. Over the last few years the 
access to alpha-synuclein-based PD models has allowed this first question to be further explored [22]. 
These models not only offer better opportunities to more faithfully replicate the alpha-synuclein 
related pathology seen in people with PD, but the lesions so induced evolve slowly over time in 
contrast to the far more rapid time course of acute toxin models of PD. Using such alpha-
synucleinopathy models,  studies designed to reproduce the type of neuroprotective and restorative 
effects of GDNF, consistently seen in MPTP and 6-OHDA models, have so far failed [23, 24].  
In a follow-up study performed in the AAV-alpha-synuclein model [25], Decressac et al. (2012) 
suggested that this could be due to a failure of alpha-synuclein overexpressing nigral neurons to 
respond to GDNF. This, the authors postulated, could be due to downregulation of the GDNF receptor 
RET, mediated by a reduced expression of the DA related transcription factor, nuclear receptor related 
1 protein (Nurr1). Nurr1 is known to regulate RET expression in DA neurons [26] and the two are thus 
closely related.  
In human PD post mortem material, Nurr1 has been shown to be down-regulated in DA neurons that 
overexpress alpha-synuclein [27] and a similar downregulation of Nurr1 is also seen in alpha-synuclein 
overexpressing neurons in the AAV model of PD. This, in turn, is accompanied by a marked reduction 
in the expression of RET [25]. The dependence on Nurr1/RET expression is further supported by an 
experiment performed in Nurr1 deleted mice showing that the ability to respond to GDNF is abolished 
in DA neurons lacking Nurr1 [25].  
The findings obtained in the AAV-alpha-synuclein model should however be interpreted with caution. 
The cellular levels of alpha-synuclein obtained in this model are artificially high (4-5-fold above 
normal) and thus may not reflect the milieu in the affected DA neurons in the PD brain. Furthermore, 
showing that RET expression is reduced in the human PD brain has proven inconclusive (see Su et al. 
2017 for a dissenting view [28]). 
In summary, the preclinical data suggests that GDNF can rescue DA neurons and their projections in 
the nigrostriatal pathway in a range of toxin animal models but  the ability to rescue may be different 
in the context of the alpha synuclein pathology that is seen in the brain of people with PD.  
THE EARLY CLINICAL TRIALS 
The move from the lab to the clinic is always challenging and in order to assess progress and success, 
new agents are often evaluated against four key elements. These include whether the drug (in this 
case GDNF for PD):  
• Reaches its proposed site of action at sufficient concentrations (namely the DA nigrostriatal 
pathway);  
• Shows target engagement at that site in a measurable way (GFRa1/RET signalling leading to 
positive changes in this DA system);  
• Displays functional downstream pharmacological effects (shows sprouting, growth and /or 
survival of DA fibres/synapses in the presence of an ongoing degenerative disease process);  
• Exhibits improvement in the relevant phenotype of the treated individuals (better motor 
performance around measures known to be sensitive to this DA network). 
 
The first of these criteria falls under the umbrella of delivery, the latter three provide a basis for 
potential efficacy, if delivery sufficient to cover the putamen can be achieved. In the sections below 
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we consider the open-label and double-blind, placebo-controlled clinical trials to-date in which 
recombinant human GDNF has been directly administered to people with PD. This will be followed by 
a description and discussion of the clinical studies where a related trophic factor NRTN was 
administered as a viral vector injection to the basal ganglia as well as an ongoing GDNF gene therapy 
trial.  
The initial double-blind randomised control trial of intracerebroventricular Injections of GDNF 
protein 
The first clinical trial of GDNF was conducted by Amgen and was a multicentre, randomized, double-
blind, placebo-controlled study of intracerebroventricular (ICV) administration of GDNF [4]. Monthly 
ICV injections were given via an intraventricular cannula inserted in the right frontal horn using 
standard stereotactic techniques. This was a dose escalation study with five dosage arms (25 µg, 75 
µg, 150 µg 300 µg and 4000 µg) with 7-8 patients receiving active drug and 2-3 patients receiving 
placebo for a period of 8 months followed by an open-label extension period of up to an additional 20 
months giving maximum single doses of up to 4,000 µg in 16 subjects. The primary outcome variables, 
the change in “practically defined OFF” and ON motor Unified Parkinson’s Disease Rating Scale 
(UPDRS) scores, were not significantly different from placebo in any of the active treatment groups 
apart from a mild but significant worsening in OFF scores in the 75 µg group and ON scores in the 300 
µg group. Adverse effects were more common in the active treatment groups and included anorexia, 
weight loss (> 5% body weight), hyponatremia and the unexpected finding (at the time) of sensory 
symptoms such as paraesthesia and Lhermitte’s phenomenon.  
Although the adverse effect profile indicated that GDNF administered by ICV injection was having 
biological effects (the anorexia and weight loss were thought to be due to its action in the 
hypothalamus), this approach did not improve the clinical state of the patient.  
It was postulated that this lack of benefit could relate to a failure of GDNF to reach and mediate effects 
in the target tissue (putamen and indirectly the substantia nigra) [4]. Supporting this hypothesis was 
a report of the post-mortem assessment of a single patient from this trial [29]. In contrast to 
experiments in monkeys, where GDNF immunoreactivity was observed within the caudate nucleus 
ipsilateral to the infused ventricular frontal-horn and in the septum bilaterally (although whether this 
was sufficient to  activate RET signalling was not assessed), the human post-mortem evaluation 
demonstrated no intra-parenchymal diffusion of GDNF across the cerebrospinal fluid:brain barrier 
from the ventricular cavity to the relevant basal ganglia structures. As such, it was to be expected that 
the autopsied tissue failed to demonstrate evidence of significant regeneration of nigral neurons and 
their fibres [29].  
While this first in-human trial failed to hit its primary end point, the above results showed that monthly 
infusions of a biologic-agent unable to penetrate the blood-brain-barrier was well tolerated and 
“relatively” safe even when high doses of GDNF were given (4000 µg) [4]. However, the lack of 
parenchymal penetration coupled with an absence of motor benefit led on to further trials with 
infusions directly to the putamen.  
The initial open label trials of intraputaminal Injections of GDNF protein 
To ensure that GDNF reached the DA terminal plexus within the posterior-dorsal striatum, two small 
open label studies evaluated direct-to-putamen continuous (rather than bolus) catheter infusions of 
GDNF [30, 31]. To effect continuous infusions, GDNF was administered from subcutaneous pumps 
placed in the abdomen connected to a single catheter to each putamen in a 5 patient cohort in Bristol, 
UK and to a single-sided unilateral catheter only in a 10-patient cohort studied in Kentucky, USA. The 
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Bristol group initially reported after 6 and 12 months as did the Kentucky group [30, 31]. Doses in the 
Kentucky study were escalated to 30µg per day and in the Bristol trial, patient’s doses were on average 
30µg per day. Some patients did receive even higher doses (> 30µg GDNF per day) but this produced 
high signal changes on MRI in the putamen – changes which resolved with dose reduction. 
Both of these small open label studies reported marked benefits in UPDRS motor (part III) scores in 
the practically defined OFF state with a mean reported improvement of approximately 30%-40%. 
Changes in diary fluctuations were equally encouraging at this open-label stage [30, 31] although it 
should be noted that the changes were bilateral even in patients who had been in receipt of unilateral 
infusions for reasons that were not clear.  
In the Bristol study, 18-fluorine-dihydroxyphenylalanine ([18F]DOPA) positron emission tomography 
(PET) scans showed an increase in tracer uptake mainly around the catheter tip, which potentially 
represented sprouting of remaining terminals, supported in part by a subsequent single case post 
mortem study [32].  
In the Kentucky study, there was one Serious Adverse Event (SAE) when the catheter became exposed 
which was associated with oedema around the catheter track in the putamen of this same patient. 
Three patients reported mild tingling sensations in the forehead, neck and lower back and two 
patients experienced transient Lhermitte’s phenomenon.  Seven patients developed antibodies to 
GDNF without clinical sequelae.  High resolution MRI scans revealed that there was no evidence of 
GDNF-induced cerebellar toxicity, which became more of a concern in some of the later preclinical 
non-human primate studies with GDNF (see below). Finally, all improvements in UPDRS scores were 
lost within 9-months of stopping the GDNF infusions.   
Based on these encouraging open label observations, a prospective, double-blind, placebo-controlled 
trial of continuously infusing GDNF to the putamen was initiated. 
DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS  
The Amgen trial 
Amgen sponsored the first double-blind trial involving direct intra-putaminal delivery of GDNF. In this 
multicentre trial, patients were randomized 1:1 to receive bilateral continuous intra-putaminal 
infusions of either GDNF at a dose of 15 µg/putamen/day or placebo [33]. One catheter was 
stereotactically placed on each side with its tip targeted to the posterior-dorsal putamen and attached 
to a separate SynchroMed pump (Medtronic), implanted subcutaneously over the patient’s abdomen. 
The primary end point was the change in UPDRS motor score in the practically defined OFF condition 
at 6 months. Secondary end points included other UPDRS scores, motor tests, dyskinesia ratings, 
patient diaries, and [18F]-DOPA uptake on positron emission tomography (PET) imaging. Patients were 
stratified by baseline UPDRS OFF motor score (<44, > 45) and 30 subjects (15 in each group) were 
calculated to be needed to give a 90% power to detect a between group difference of 25% in the 
percent change in UPDRS OFF motor score. 
34 patients were implanted and randomized; 17 received GDNF, (all completed the trial), and 17 
received placebo (with 16 completing the trial, and one discontinuing due to pump site infection). At 
6 months, the mean percentage change in OFF UPDRS motor score was -10% in the GDNF group 
compared to -4.3% in the placebo group which was not statistically significant. Secondary end point 
results were also similar between the groups. There was no significant relationship between the 
change in motor scores and the catheter tip location. In the two thirds of paired evaluable PET scans 
(1/3 of paired scans were excluded due to head movement artefact) there was a 32.5% treatment 
9 
 
difference favouring GDNF in mean [18F]DOPA influx constant (p =0.019) but this did not correlate with 
changes in the OFF UPDRS motor scores. Procedure- and device-related complications were not 
uncommon while treatment related complications were infrequent. The marked anorexia and weight 
loss observed in the higher dose ICV study were not seen. Serious, device-related adverse events 
required surgical repositioning of catheters in two patients and removal of devices in another  [33].  
Three patients, one in the double-blind phase and two in the open label extension, developed 
neutralizing anti-GDNF antibodies - again without any obvious clinical sequelae- which may relate to 
the way the GDNF was delivered with leakage to the periphery, and activation of the immune system. 
Furthermore, contemporaneously, new toxicological studies in non-human primates (NHPs) found 
focal limited loss of Purkinje cells and near complete loss of molecular and granule cell layers in 3/5 
monkeys rapidly withdrawn from 3 months of unilateral infusions of much higher doses of GDNF (100 
μg/putamen/day) while one monkey continuing on treatment was found to have milder cerebellar 
cortical pathology [34]. 
As a result of this combination of a negative clinical double-blind placebo-controlled trial result, the 
finding of neutralizing antibodies in a small number of patients and concerns about the NHP 
toxicological findings, Amgen chose to terminate their GDNF program for PD. This led to a vigorous 
debate between various researchers and patient groups as to why the double-blind trial and the open-
label studies had come to different conclusions. These included: 
1. The potential for a major placebo effect in open-label trials given it involved an invasive surgical 
approach and problems in maintaining true clinical equipoise. However, it should be noted that in the 
double-blind study there was no major placebo effect, but rather an absence of a positive clinical 
effect in either group.  
2. Differences in dosages given, in particular higher doses were generally used in the open label 
studies, although benefit had also been claimed with lower doses in these early studies;  
3. Differences in delivery including catheter dimension and design. In general, catheter dimensions 
including its external diameter, design (no step, stepped or recessed stepped) and number of 
catheters inserted along with implantation technique could all have an effect on the extent to which 
the agent was delivered and remained at the target site. In addition, differences in the diffusion of the 
agent across the target structure could also have impacted on the total volume of putaminal tissue 
exposed to study drug (see below) [35] and thus its potential therapeutic effectiveness. All of this has 
led to the development of new convection enhanced delivery systems (see below). 
4. Differences in the patients selected for trials, in particular whether more advanced patients with 
more severe DA losses were recruited to the double-blind study.   
Given this uncertainty, there was a feeling in some quarters that this therapy should not be abandoned 
at this stage - a position reinforced by further observations from the original open-label Bristol cohort 
[32, 36, 37]. This included the fact that the original five subjects who continued to receive continuous 
infusions from 12 to 24 months and beyond, all maintained their improved UPDRS part II and part III 
OFF scores compared to baseline, consistent  with their improved [18F]DOPA PET data [36]. Finally, 
one subject who had been infused continuously for 39 months and then reviewed at 36 months after 
GDNF cessation, continued to experience a major clinical benefit. This benefit was accompanied by 
[18F]DOPA PET putaminal uptake that continued to show an improvement compared to pre-treatment 
scans [37]. Although a single case, this did support the concept that GDNF might still work if 
methodological aspects of its administration were improved. Thus, a new GDNF trial was proposed. 
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The recent Bristol study 
This new double-blind investigation of directly administered GDNF took the form of a randomised, 
placebo-controlled, single-centre trial sponsored by the UK National Health Service (and funded by 
Parkinson’s UK and The Cure Parkinson’s Trust) which started in 2012 [38] (NCT03652363). Patients 
selected were 35-75 years old, had motor symptoms for 5 or more years, with moderate disease 
severity in the OFF state (Hoehn and Yahr stage 2-3 and a UPDRS motor score between 25-45) and 
motor fluctuations (average of at least 2.5 hours of OFF time per day on 3-day fluctuation diaries). 
They all had marked levodopa responsiveness as defined by a ≥40% improvement in UPDRS motor 
score following a levodopa challenge after a practically defined OFF period.  Importantly, the major 
difference with this trial with what had gone before was the use of a new delivery device designed to 
establish excellent coverage of the putamen.  
Once implanted with this new intermittent enhanced drug administration system that enabled 
convection enhanced delivery (CED), patients were randomised. Post-randomisation, patients 
received a total of 10 study treatments at 4-weekly intervals (Weeks 0 to 36). At each treatment, 400 
µL of infusate (300 µL GDNF or placebo, followed by 100 µL aCSF) was delivered per catheter into the 
post-commissural putamen at a GDNF concentration of 0.2 µg/µL. Thus, the total GDNF dose given 
every 4 weeks was 240 µg (120 µg/putamen given as 60 µg/catheter).  
The results of this trial were published in February 2019 [38]and it revealed that the trial did not reach 
its prespecified primary endpoint; the mean OFF state UPDRS motor score decreased by 17.3±17.6% 
in the active group and 11.8±15.8% in the placebo group. A range of secondary and supplementary 
efficacy endpoints also failed to show significant differences between the groups as well.  In contrast 
to the non-significant clinical results, the [18F]DOPA PET findings were positive. Between baseline and 
Week 40 there was no change in the placebo group, whereas in the GDNF group there were significant 
changes across the putamen (in a graded fashion ranging from 25% anteriorly to 100% in the posterior 
putamen) but not in the caudate (which acted as an internal control). These marked relative 
percentage increases, while statistically significant, still meant that the absolute improvement was 
only to a level that was 50-60% of that seen in the normal intact posterior putamen which may explain 
why the treatment did not result in significant clinical changes. 
At the conclusion of this double-blind study, all patients had the chance to enrol into an open label 
extension trial that used the same GDNF dose regimen and intermittent infusion parameters as for 
the initial double-blind study. This open label extension trial, also lasted 40 weeks, and was initiated 
before the results from the double-blind parent investigation were known. It was undertaken primarily 
to gain longer term safety data and to gather further exploratory information on GDNF clinical effects 
over a more prolonged period of repeated tissue exposures [39]. 
The primary endpoint of this extension study was the percentage change from baseline (Week 0) to 
Week 80 in the practically defined OFF state UPDRS motor score, comparing the group that had 
received GDNF in the initial trial followed by open-label GDNF (GDNF/GDNF) versus the group that 
received placebo in the parent investigation followed by open-label GDNF (placebo/GDNF)(in effect a 
delayed-start design). Secondary endpoints included absolute change from baseline in OFF and ON 
state UPDRS part II and part III scores and change from baseline in diary ratings. A further pre-specified 
secondary endpoint included comparing Week 80 UPDRS scores in the GDNF/GDNF group against 
Week 40 scores in the placebo/GDNF group (i.e., at the end of the placebo treatment).  
All 41 parent study participants were enrolled into the extension study, and all were included in the 
analyses.  Again, there were no significant differences. Comparing baseline (Week 0) to the end of 
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treatment (Week 80), the OFF state UPDRS motor score improved by 26.7±20.7% (mean ± standard 
deviation) in the GDNF/GDNF group and by 27.6±23.6% in the placebo/GDNF group. Likewise, none 
of the secondary or supplementary outcomes spanning the entire 80-week period were significantly 
different outside changes in L-DOPA equivalent dose (the increase in the daily L-DOPA equivalent dose 
from baseline to Week 80 was smaller in the GDNF/GDNF group (59±194mg) than in the 
placebo/GDNF group (289±365mg) [35].  
Treatment emergent adverse events (TEAEs – events commencing post initiation of GDNF or placebo 
infusions) were reported for all 41 patients. No patient had a TEAE that led to discontinuation of study 
medication. Of the eight serious TEAEs, three were considered to be device related and included two 
occurrences of a hypertrophic skin reaction around the port site that required surgical skin thinning 
and a possible port site infection that occurred approximately 15 weeks into the treatment phase and 
required inpatient treatment with oral antibiotics.  
Two patients enrolled into the double-blind study did not proceed to randomisation and were 
withdrawn prior to the start of treatment because they failed the post-surgery eligibility criteria. One 
patient experienced a mildly symptomatic putaminal ischemic stroke coincident with the initial test 
infusion. The patient recovered completely but was withdrawn to avoid unnecessary risks. The second 
patient suffered a small asymptomatic haemorrhage in both putamina during the initial test infusion.  
Blood sample analyses showed no measurable GDNF plasma concentrations and no GDNF-binding 
serum antibodies in GDNF-treated patients at any point. This contrasts with the double-blind Amgen 
study and the earlier open label studies and may relate to the different delivery devices and delivery 
regimens that were used in each trial. 
In summary, these two studies have shown that direct infusions of GDNF administered in a manner to 
achieve CED can be given every 4-Weeks over 18 months in a fashion that patients found tolerable. 
Employing this approach, as evidenced by a combination of direct Gadolinium infusion through the 
delivery system and improvement in [18F]DOPA PET uptake, appeared to achieve accurate and whole 
putamen-wide target tissue delivery with some evidence of target receptor engagement using PET 
imaging.   Despite this apparent optimisation of delivery, however, the clinical primary and secondary 
endpoints in both trials were negative. Whilst the partial restoration in PET signal may alleviate some 
of the concerns around insensitivity to GDNF in the face of an alpha-synucleinopathy or that patients 
more than 5 years from the point of diagnosis have no terminals left to restore, the fact remains that 
improvement in [18F]DOPA PET signal cannot be used as evidence for improvement in functional 
pharmacology, especially as this tracer has also been said to label inflammation [40] . Questions 
therefore remain over whether the lack of significant benefit in placebo-controlled trials to date 
reflects therapeutic ineffectiveness or whether this would be resolved with an increased dose and 
exposure of mammalian cell made GDNF coupled to treating patients with earlier stage disease.  
GENE THERAPY TRIALS WITH NRTN AND GDNF  
In contrast to the immense logistical challenges and potential safety concerns associated with 
continuous or repeated long-term delivery of recombinant GDNF protein, gene therapy promises 
sustained, durable and localized production of properly folded biologically active GDNF following a 
one-time dosing procedure. Several clinical studies have now been conducted in PD, including a multi-
phase program of NRTN gene transfer, a homolog of GDNF, and more recently a Phase 1 clinical safety 
trial of GDNF gene transfer. Both the NRTN and GDNF gene therapy programs utilized gene transfer 
vectors derived from the non-pathogenic adeno-associated virus serotype 2 (AAV2) with a constitutive 
CMV promoter. These vectors appear to have a favourable safety profile for neurotrophic factor gene 
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delivery in PD, in addition to which AAV2 has an exclusive neuronal tropism and restricted distribution 
when directly delivered to the brain [41] - thus minimising off target side effects.  
The initial preclinical studies exploring this approach demonstrated that GDNF and NRTN gene delivery 
conveyed efficient protection against MPTP/6-OHDA lesions when the gene transfer was performed 
prior to, or shortly after, neurotoxin exposure.  However, in an attempt to more closely mimic both 
early and later stages of PD a more refined MPTP model was developed in non-human primates (NHPs 
[21, 42]). Using this model, animals with established parkinsonian signs were  randomized to receive 
either 1) AAV2-GDNF (9.9 x 1011 vector genomes, vg; n= 8), or 2) sham PBS (n=7) intraputaminal 
infusions via CED [21] , and were followed for 1, 6, 14, or 24 months.  
In one of these NHP studies, it was demonstrated that there were marked functional motor 
improvements following AAV2-GDNF (mean 56% reduction of motor rating scores) in both the 
moderately and severely lesioned MPTP monkeys. This motor recovery directly correlated with 
increased 6-[18F]Fluoro-L-M-tyrosine (FMT) PET uptake that remained stable throughout the 24-
month time point and which also correlated with enhanced dopamine and dopamine metabolites 
when assayed from tissue homogenates from these same animals. Increased TH-immunoreactive (TH-
IR) fibre density was also seen in the partially lesioned hemisphere (equivalent to “early” PD) receiving 
the AAV2-GDNF but was much less prominent in the severely lesioned side (comparable to advanced 
PD). Together these findings suggested that intraputaminal infusions of AAV2-GDNF were safe and 
that greater parenchymal GDNF levels (~24ng/mg protein) were well-tolerated, without the adverse 
effects seen with protein infusions of GDNF (e.g., weight loss) [4, 33]. This also indicates that GDNF is 
capable of restoring dopaminergic terminals with an associated significant recovery of motor function, 
particularly in the partially lesioned conditions.  In addition, there was strong evidence that GDNF 
delivery provided greater potential for intrinsic TH-IR positive sprouting in earlier rather than later 
stages of nigrostriatal degeneration.   
These and related studies [43]  also found that there was anterograde transport of AAV2-GDNF, via 
direct and indirect connections, which was independent of the degenerating nigrostriatal 
dopaminergic (DA) neurons [43, 44] and their capacity to retrogradely transport GDNF protein. This 
mechanism resulted in the broad expression of GDNF from the putamen to the substantia nigra (SN) 
pars reticulata, despite varying degrees of nigrostriatal DA neurodegeneration and raised the potential 
that this therapeutic may provide distinct advantages through rebuilding DA nigrostriatal networks 
within the PD brain.  
This NRTN preclinical work led to clinical trials that were performed by Ceregene Inc. using the AAV-2 
serotype and the NRTN transgene, the first of which was an open label clinical trial [45]    
(NCT00252850). Twelve patients aged 35-75 years with a diagnosis of PD for at least 5 years, in 
accordance with the Parkinson’s UK Brain Bank Criteria, received bilateral, stereotactic, 
intraputaminal injections of AAV2-neurturin (CERE-120). The first six patients received doses of 
1.3x1011 vector genomes (vg)/patient, and the next six patients received 5.4x1011 vg/patient. The 
treatment was well tolerated with no side effects and a number of clinical endpoints suggested 
improvement. However, disappointingly there was no increase in 18F-DOPA uptake on PET imaging.  
This initial trial was followed by a multi-centre randomized (2:1) double-blind trial comparing 
intraputaminal injections of AAV2-neurturin to sham surgery  in 58 PD patients [46].  An infusion 
volume of 40ul of vector was injected into each putamen with subjects in the active treatment arm 
receiving a dose of 5·4 × 10¹¹ vg/patient.  Disappointingly, there was no significant difference between 
the two groups based on UPDRS Part III motor scores in the OFF state at 12 months post-transduction 
- the primary endpoint. However, a significant placebo effect was noted, with a 6-point reduction in 
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UPDRS seen at 3 months in the sham group, which persisted for the duration of the study.  However, 
a pre-specified post-hoc analysis suggested that those patients blindly assessed at the 15-18 months 
post-treatment time point may have had some benefit, although there was no controlling for multiple 
comparisons. In addition, it should be noted that the whole cohort could not be followed blindly out 
to these time points due to the ending of the trial and the blind being broken at 12 months. This may 
have created a bias in the effect seen.  
Histological data from patients who died from events unrelated to the procedure, indicated that NRTN 
was being expressed within the vicinity of the injection sites, and that this resulted in focal 
upregulation of TH, but to an extent that was probably insufficient to provide any clinical benefit. 
Additionally, there was very limited NRTN seen in nigral neurons, suggesting that severity of the 
nigrostriatal axonopathy in these advanced PD patients did not allow sufficient retrograde transport 
of NRTN to the nigral perikarya to provide neurorestorative effects [47]. 
Based on the small area of transduction, the lack of NRTN expression in nigral neurons, the perceived 
defect in retrograde transport and the potential for changes to occur at a longer time-point, a second 
randomized double-blind trial comparing higher putaminal volumes plus a direct injection into the 
nigra was undertaken [48]. Fifty-one patients were enrolled in this multi-centre trial and  randomly 
assigned (1:1) to receive either bilateral AAV2-NRTN (180 ul injection volume per hemisphere) into 
the substantia nigra ( 2.0 × 1011 vg/patient, 15 µL x 2 infusions) and putamen (1.0 × 1012 vg/patient, 50 
µL x 3 infusions), or sham surgery. Again, no statistically significant clinical differences were seen in 
UPDRS Part III motor OFF scores at 15-months (primary endpoint) between the active treatment and 
sham operated arms  
Following the NRTN studies, an open-label, dose-escalation Phase 1 study of AAV2-GDNF was initiated 
in 2013 (NCT01621581) [49]. In this GDNF gene therapy study, 13 (of an intended 24) participants with 
advanced PD received bilateral magnetic resonance imaging (MRI)-guided, CED intraputaminal 
infusions of AAV2-GDNF (9 x 1010 (n=6), 3 x 1011 (n=6), 9 x 1011vg (n=1); delivered in a 450 µL volume 
per putamen. Safety and tolerability of AAV2-GDNF intraputaminal delivery by CED was confirmed by 
real-time MRI and postoperative monitoring, with no serious adverse events (SAEs) attributed either 
to the procedure, or to the investigational product. Increased PET uptake values of 18F-DOPA were 
noted at the documented infusion sites at the 6-month time point as compared to baseline values, 
with further enhanced uptake observed at 18-months post-treatment timepoint. A trend was noted 
for earlier and more marked increases in patients with shorter disease duration. No significant 
differences were seen at 18-months between the three treated cohorts in terms of their UPDRS Part 
III motor scores or total levodopa equivalent doses. The unchanged PD motor scores and stabilisation 
of their anti-parkinsonian medications following putaminal AAV2-GDNF delivery might support 
possible biological effects of this therapy in participants with advanced PD but this remains unproven. 
Several key changes were made as part of the AAV2-GDNF Phase 1 study design compared to prior 
direct infusion studies in PD conducted in the early 2000s, including: 
a) the use of intraoperative MRI-guidance, and gadolinium co-infusion with AAV-GDNF  
b) using a reflux-resistant delivery cannula with a stepped design to increase distribution within 
the target putamen while reducing off-target leakage;  
c) allowing the visualisation and monitoring of CED infusions in real-time with an ability to 
surgically modify the cannula position and infusion parameters to maximise the putaminal 
coverage, and  
d) increasing the infusion volumes up to 450 µL per putamen, 3 times greater than the volume 




Despite these key modifications in methods, the average putaminal volumetric coverage documented 
by retrospective interim analysis of MRIs was only 26%, much lower than that anticipated to be 
required for a meaningful clinical benefit. In part, this limitation in putaminal coverage may have been 
due to the transfrontal surgical approach to the putamen, where the trajectories are perpendicular to 
the long axis of the target volume. This inability to broadly cover the putamen with this standard 
surgical approach may have also been a relevant disadvantage in the AAV2-NRTN and earlier 
recombinant GDNF protein infusion studies, where there was minimal putaminal transgene 
expression or effects with small localised changes relative to the radiographic improvement displayed 
via 18F-DOPA PET imaging .   
Although long term follow-up for the Phase 1 adeno associated virus (AAV) 2-GDNF cohorts is ongoing, 
enrolment was closed following the interim analysis, due to the insufficient putaminal coverage (mean 
of 26%).  Other studies of a AAV2-L-aromatic amino acid decarboxylase (AADC) gene therapy for PD 
[50], however have shown that delivering volumes up to 1800 µL per putamen using a CED approach 
is feasible with a good safety profile and providing putaminal volumetric coverage of  >50%. More 
importantly, this AAV2-AADC PD gene therapy investigation has provided convincing evidence that 
the clinical benefit improved concurrently with increases in volume of vector delivered and thereby 
the extent of putaminal coverage. These findings underscore the importance of optimising the 
transduced tissue volume and putaminal infusion coverage as factors correlating directly with clinical 
efficacy in PD [49]. 
These latter efforts have prompted the design of a new Phase 1b trial to assess a higher dose of the 
AAV2-GDNF therapeutic in moderately advanced PD patients, (similar to those in Phase 1), as well as 
in subjects with early disease (namely within 5 years of PD onset). Furthermore this new study will be 
using a posterior (occipital) trajectory to each putamen, (paralleling the long axis), that allows shape-
fitting CED of higher infusion volumes, thereby improving putaminal coverage and GDNF production 
levels more uniformly throughout the putamen [51]. This posterior putaminal approach is similar to 
that recently reported  in the  GDNF protein infusion study [38] and has also been safely performed 
using MRI-guidance and CED, in the ongoing AAV2-AADC study (NCT03562494)(See Figure 1). 
 
WHERE NEXT? 
The question as to whether GDNF has a competitive future in the treatment of PD is still unclear. A 
number of conclusions can be drawn from the studies undertaken to date with GDNF and related 
factors (see Table 1) along with a number of recommendations about what another trial with GDNF 
should consider and thus might look like (see Table 2). In particular, it was felt that a viral delivery 
system using some of the newer modified approaches would be advantageous given the one-off 
nature of the surgery compared to the relative complexity of the neurosurgery needed to implant the 
infusion delivery systems used in the recent GDNF trial and consequent requirement for on-going 
infusions. That said, the efficacy of GDNF may require intermittent rather than continuous RET 
receptor stimulation and, whilst in the development phase, understanding the exact dose 
administered and retaining the ability to reduce and stop dosing may have utility.  In addition, it seems 
logical to assume that the individuals most likely to benefit from such a treatment would be those 
individuals with most neurons and fibres left to rescue, namely patients with early stage Parkinson’s 
with evidence of fibre loss restricted to the dorsal striatum [52] - where the therapeutic agent would 
be targeted. If such an approach were recommended, then ensuring the patient actually has Dopa-
responsive PD will be critical, and the use of imaging to help support such a diagnosis would be 
essential - including both DA imaging as well possibly fluorodeoxyglucose (FDG) PET (for both 
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diagnostic stratification and corroboration of functional target engagement) [53]. In addition, the 
exclusion of certain genetic forms of parkinsonism may be wise, for example GBA heterozygote 
patients, given that they progress more quickly especially with pathology outside of the DA 
nigrostriatal pathway [54, 55] .  
 Whether an adjunct therapy to upregulate Nurr1 would be required is still unclear given the clinical 
data to date, but the preclinical data would suggest this. However, there is no such agent that has yet 
been identified with a safety profile that is acceptable and even if one existed, questions still arise as 
to how long such a therapy should be given. Coupled to this is a need to better understand the optimal 
dose of GDNF and volume of its distribution, to ensure that the treatment has the best chance of 
showing a clinical effect, and that this effect is the maximal one that one could expect for that agent. 
Finally, since E. coli cannot form seven disulphide bonds correctly and glycosylate GDNF, the use of 
mammalian cells to make GDNF should be considered if protein infusions are being considered 
although this brings with it major cost implications.  
As to what any trial should look like, there is still much debate as to what primary end-point should 
be used and at what time point, and input from the patient community on this will be vital going 
forward. However, this end point should reflect changes in those clinical aspects of PD that respond 
to dopaminergic interventions given this is the pathway being targeted by these treatments. A double-
blind sham surgery trial would be the preferred design for future studies, although whether more 
optimisation of the delivery of GDNF should be carried out before such a trial is undertaken is 
debatable.  Overall there was a consensus from the workshop, that longer trials may be better for fully 
exploring whether this agent can mediate neurorestoration and thus waiting at least 18 months from 
the start of any therapeutic intervention would increase the chances of seeing any such effects. In 
addition, using composite end points may also have some merit given that the use of any single one, 
such as the UPDRS part III score, has limitations. As to what that composite clinical end point should 
look like is unclear as regulatory agencies are currently not accepting these for licensing purposes. 
However, one that has recently been proposed relating to the recent Bristol GDNF trial, PDCORE, 
embraces good quality on-time; activities of daily living and reflects previous participant feedback 
(Brain Communication 2020- in press). 
In addition to the use of wild type GDNF and NRTN given as protein deliveries or a gene therapy, other 
similar approaches for treating PD were also discussed. In pre-clinical studies, new GDNF and NRTN 
mutants with improved diffusion and stability have shown beneficial effects [56, 57] . Furthermore, to 
overcome the limitations of some of the pharmacokinetic properties of the GDNF and NRTN proteins, 
a blood-brain-barrier penetrating small molecule GDNF receptor agonist has recently been developed. 
This compound activates RET-dependent intracellular signaling cascades in DA neurons both in vitro 
and in vivo and also stimulates the release of dopamine in the mouse striatum – all of which suggests 
that this agent could be a novel future treatment of PD [58] .  
In this respect, Cerebral dopamine neurotrophic factor (CDNF) is a relatively recently discovered 
endoplasmic reticulum (ER) located, but also secreted, protein that protects and restores the function 
of DA neurons in rodent and non-human primate models of PD and does so more effectively than 
GDNF [59]. CDNF is very different from other known trophic factors– it has a unique structure and 
mode of action protecting neurons by inhibiting cell death, regulating endoplasmic reticulum (ER) 
stress, the unfolded protein response (UPR) and reducing inflammation [60] . In addition, CDNF 
rescues only ER-stressed or degenerating neurons and does not influence naïve healthy neurons. This 






This special workshop comprehensively covered the studies evaluating GDNF and the related trophic 
factor NRTN in PD both preclinically and clinically. It critically appraised the work so that conclusions 
could be drawn as to what has been shown and what has not been shown with these agents. It was 
generally agreed that GDNF and NRTN have worked relatively well in neurotoxic animal models of PD 
but that their translation to the clinic has so far failed to show a major impact - perhaps highlighting 
the predictive limitations of toxin animal models being commonly used in the preclinical space in PD 
and the way we plan clinical trials.  
Clinically, there is evidence that these neurotrophic factors are able to rescue the expression of 
tyrosine hydroxylase (TH) in the human PD brain with some suggestion of a clinical correlate. 
Nevertheless, the current size of any such effect is not competitive compared to what is already 
clinically available for the DA-related features of PD (DuoDopa®; deep brain stimulation (DBS); lesion 
surgery such as pallidotomy; apomorphine pumps etc) and this may also be the case with new agents 
that are currently being trialled in PD around dopamine rescue (stem cell derived DAneurons; CDNF, 
“dopamine” gene therapies). However, it must be realised that these agents are uniquely designed to 
restore and regenerate the dopaminergic pathway which is very different from these other 
symptomatic therapies.  
In conclusion, further work is needed to understand better what can be achieved with GDNF and 
related factors in the clinic to improve the lives of patients with PD - although ultimately whether it 
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Figure: Transfrontal versus Posterior (occipital) 
trajectories utilizing CED. 
MRI-guided stereotactic approaches for vector delivery 
to the putamen utilizing convection enhanced delivery 
(CED) and stepped cannulae. This approach allows for 
precise targeting, shape-fitting infusions, and larger 
delivery volumes to improve the extent of transduced 
putaminal tissue, thereby increasing transgene 
production capacity. With the transfrontal approach, the 
cannulae are oriented to the short axis of the putamen 
limiting vector coverage to <30%, often requiring 2-3 
tracts. The posterior (occipital) approach maximizes the 
delivery by paralleling the putaminal long-axis, requiring 
only 1 tract, which achieves >50% putaminal vector 
coverage with larger infusion volumes.    
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TABLE 1- SUMMARY OF MAIN FINDINGS ON THE EFFECTS OF GDNF AND RELATED FACTORS IN 
MODELS AND CLINICAL TRIALS IN PD 
• Studies have shown a statistically significant response in some patients, but these are not 
consistent, and the majority of studies have been negative in terms of reaching their primary 
outcome; 
• Striatal dopamine has increased in most patients in receipt of GDNF as evidenced using 18F –
dopa PET imaging; 
• There is little evidence of sufficient retrograde transport of GDNF/NRTN to the substantia 
nigra in patients when the agent is delivered into the striatum; 
• Post mortem studies show that where there is expression of GDNF/NRTN there is some 





TABLE 2; FACTORS TO CONSIDER IN FUTURE CLINICAL TRIALS WITH GDNF AND RELATED FACTORS 
IN PD  
What form should the GDNF be given in? 
• A gene therapy approach was favoured over protein infusions given the complexity of the 
neurosurgical intervention required for the former and the burden this places on the 
patients with Parkinson’s disease. 
• Consider using mammalian cell produced GDNF and NRTN proteins. 
 
Patient type; 
• Younger patients with marked L-dopa response and no major ventral striatal dopamine loss 
on dopamine imaging. 
• Avoid certain genetic forms/variants associated with Parkinsonism (Parkin; GBA) 
 
Disease stage; 
• Avoid late stage disease 
 
Dose given; 
• Depends on the neurotrophic factor that is being delivered, but probably need higher doses 
than have been trialed to date (with the exception of the first ICV trial of GDNF) 
 
Volume given; 
• Depends on delivery system but need to give up to ~1ml per striatum treated 
 
Delivery device; 
• Several now in existence- e.g. Renishaw , Clearpoint 
 
Need for adjunct therapies; 
• Not proven to be needed, although preclinical data suggests that Nurr 1 agonists may 
enhance the efficacy of GDNF- so perhaps this should be included as part of further trials  
 
Need for imaging? If so with what? 
• F-dopa PET imaging seems to have provided useful information in trials to date, but need for 
other PET markers looking DA turnover/release as well as network reconstruction 
 
Trial end points- what and when; 
• Standard measures UPDRS part 2 +/-  PDCore scores at 18-24 month as the primary end 
point.  
• Sample size currently undecided given lack of major effects seen to date which would allow 





• Consider a delayed start design to the trial or a randomized double blind placebo controlled 
study 
• Keep the trial outcomes and measures simple 
• In post -mortem samples it is important to show that GDNF and NRTN have activated RET- 
dependent signalling pathways or to show direct RET receptor activation 
  
Health economics for this agent? 
• Depends on where it is positioned 
BUT although it works uniquely to restore the dopaminergic nigrostriatal, it will nevertheless 
have to compete with other “DA” therapies/interventions- new dopamine drugs; DuoDopa®; 
Deep Brain Stimulation etc and the newer dopamine gene or cell based therapies should they be 
shown to work 
• Currently it would not be competitive given the size of effects seen to date, but this may 
relate to suboptimal delivery etc 
 
 
 
